Passage Bio
PASG · NASDAQ
$3.60+$0.02 (+0.56%)TodayMarket closed ·
Prev close $3.58
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 16.1% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$2.70 | -$2.44 | +9.6% |
| Q1 FY26 | -$2.85 | -$2.16 | +24.1% |
| Q4 FY25 | -$2.62 | -$3.95 | −50.7% |
| Q3 FY25 | -$2.86 | -$2.44 | +14.6% |
| Q2 FY25 | -$4.13 | -$2.96 | +28.3% |
| Q1 FY25 | -$4.69 | -$5.00 | −6.6% |
| Q4 FY24 | -$4.16 | -$4.00 | +3.9% |
| Q3 FY24 | -$4.69 | -$6.20 | −32.1% |
Earnings calls
- Passage Bio, Inc., Remix Therapeutics, Inc. - M&A Call
- Goldman Sachs 45th Annual Global Healthcare Conference
- Special Call - Passage Bio, Inc.
- Special Call - Passage Bio, Inc.
- Goldman Sachs 44th Annual Global Healthcare Conference
- Earnings call Q4 2022
- Special Call - Passage Bio, Inc.
- Earnings call Q3 2022
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.